Sesen Bio Inc.

NASDAQ:SESN  
2.33
+0.05 (+2.19%)
Earnings Announcements

Sesen Bio Reports Fourth Quarter And Full-Year 2020 Results

Published: 03/15/2021 11:49 GMT
Sesen Bio Inc. (SESN) - Sesen Bio Reports Fourth Quarter and Full-year 2020 Financial Results and Significant Regulatory and Commercial Readiness Progress for the Company’s Lead Product Candidate Vicineum™.
Q4 Loss per Share $0.11.
Q4 Earnings per Share Estimate $-0.10 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0.8 Million
Adjusted EPS is expected to be -$0.05

Next Quarter Revenue Guidance is expected to be $0.53 Million
Next Quarter EPS Guidance is expected to be -$0.06

More details on our Analysts Page.